This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY) (D-SUNNY)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Yanbin Dong, Augusta University
ClinicalTrials.gov Identifier:
NCT01583621
First received: April 3, 2012
Last updated: February 8, 2017
Last verified: February 2017
  Purpose

Primary Specific Aim 1: To compare the dose-responsive effects of vitamin D3 supplementations on 25(OH) D, parathyroid hormone (PTH), and serum/urine calcium.

Primary Specific Aim 2: To compare the dose-responsive effects of vitamin D3 supplementations on non-invasive vascular measures including pulse wave velocity (PWV), flow-mediated dilation (FMD), carotid arterial compliance (CAC), carotid Intima-Media Thickness (cIMT), and 24-hours Ambulatory Blood Pressure (ABP) monitoring as well as casual BP.


Condition Intervention
Vitamin D Deficiency Dietary Supplement: Cholecalciferol

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Health Services Research
Official Title: Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)

Resource links provided by NLM:


Further study details as provided by Yanbin Dong, Augusta University:

Primary Outcome Measures:
  • Cardiovascular phenotypes [ Time Frame: 16 weeks ]
    Will be using non-invasive vascular measures including pulse wave velocity (PWV), flow-mediated dilation (FMD), carotid arterial compliance (CAC), carotid Intima-Media Thickness (cIMT), and 24-hours Ambulatory Blood Pressure (ABP) monitoring.

  • Primary outcome 1 dose-responsive effects of vitamin D3 supplementations [ Time Frame: 16 weeks ]
    To compare the dose-responsive effects of vitamin D3 supplementations on 25(OH) D, parathyroid hormone (PTH), and serum/urine calcium.

  • Primary Outcome 2 dose-responsive effects of vitamin D3 supplementations [ Time Frame: 16 weeks ]
    To compare the dose-responsive effects of vitamin D3 supplementations on non-invasive vascular measures including pulse wave velocity (PWV), flow-mediated dilation (FMD), carotid arterial compliance (CAC), carotid Intima-Media Thickness (cIMT), and 24-hours Ambulatory Blood Pressure (ABP) monitoring as well as casual BP.


Enrollment: 74
Study Start Date: November 2011
Study Completion Date: August 2015
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Placebo
Placebo group
Experimental: Supplementation arm 1
cholecalciferol 18000 U/month for 4 months
Dietary Supplement: Cholecalciferol
The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).
Experimental: supplementation arm 2
cholecalciferol 60000 U/month for 4 months
Dietary Supplement: Cholecalciferol
The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).
Experimental: Supplementation arm 3
cholecalciferol 120000 U/month for 4 months
Dietary Supplement: Cholecalciferol
The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).

  Eligibility

Ages Eligible for Study:   13 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. African-Americans (blacks)
  2. Age 13-45
  3. Overweight/obese (BMI ≥ 85th percentile for their age and gender for age 13-17 and BMI ≥ 25 kg/m2 for age 18-45)
  4. Relatively healthy (no medical history of any heart, lung, endocrine or malignant disorder)
  5. Non pregnant
  6. Not on any medication or vitamin supplements that can influence the study outcomes
  7. Serum 25 hydroxy Vitamin D (25[OH] D) levels ≤ 20 ng/ml (50 nmol/L) at the time of screening

Exclusion Criteria:

  1. Not meeting any one or more of the above criteria
  2. Females who become pregnant/test positive on urine pregnancy test during the screening or any of the testing visits
  3. Anyone who is taking any multivitamin supplements that contains vitamin D
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01583621

Locations
United States, Georgia
Georgia Prevention Institute
Augusta, Georgia, United States, 30912
Sponsors and Collaborators
Augusta University
Investigators
Principal Investigator: Yanbin Dong, MD, PhD Augusta University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Yanbin Dong, Professor, Department of Pediatrics, Augusta University
ClinicalTrials.gov Identifier: NCT01583621     History of Changes
Other Study ID Numbers: pro#00000051
Study First Received: April 3, 2012
Last Updated: February 8, 2017

Additional relevant MeSH terms:
Overweight
Vitamin D Deficiency
Body Weight
Signs and Symptoms
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders
Vitamins
Vitamin D
Ergocalciferols
Cholecalciferol
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents

ClinicalTrials.gov processed this record on July 25, 2017